

## Special Issue

# Surgical Treatment of Hepatocellular Carcinoma

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver. Surgical treatment remains the most important treatment for HCC. Traditionally, surgical treatment is limited to treating the early stages of HCC. However, most cases of HCC are found at the late stages. Whether surgical treatment has a role in the treatment of HCC beyond the early stage is an important issue. This Special Issue entitled “Surgical Treatment of Hepatocellular Carcinoma” focuses on the innovation of surgical treatments. We are pleased to invite you to submit manuscripts to this Special Issue. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: surgical techniques, surgical indications, surgical outcomes, clinical trials, liver transplantation, adjuvant therapy, basic research, etc. We look forward to receiving your contributions.

### Guest Editor

Prof. Dr. Wei-Chen Lee

Department of General Surgery and Chang Gung Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 33302, Taiwan

### Deadline for manuscript submissions

31 August 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/205089](https://mdpi.com/si/205089)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)